Xyntek Appoints Matt Thompson as Vice President of Sales

Xyntek Appoints Matt Thompson as Vice President of Sales

YARDLEY, Pa., March 4, 2013 /PRNewswire/ -- Xyntek Inc., a leading provider of technology consulting and turn-key integrated Information Systems and Real Time Automated System Solutions to the world's leading Life Sciences companies, has announced the appointment of Matt Thompson as Vice President of Sales.

(Photo: http://photos.prnewswire.com/prnh/20130304/PH69795)

Prior to joining Xyntek Inc., Thompson functioned in a variety of leadership capacities with Videojet Technologies, where he averaged over 128% of his yearly quota. He is a global IT & Automation executive with 25 years of experience in the process control, machine vision & image processing, and code marking industries. During his tenure, Thompson was part of the sales team that helped grow Cognex Vision System from $60 million in revenue to $250 million over a six year period and was given the Innovators Award for helping to create a new product line called Digital Template while with Faro Technologies.

Thompson earned his Master of Business Administration from Temple University, and a Bachelor of Science degree in electrical engineering from Pennsylvania State University.

"After a long and exhaustive national search, my Team and I are pleased to have attracted to Xyntek an experienced senior level sales executive of Matt's caliber, with national reputation and credibility," says Mac Hashemian, P.E., Xyntek's President and Chief Executive Officer.

"Already Matt has added tremendous value to Xyntek's Serialization Business Unit. His knowledge and expertise in printing technology, machine vision inspection, and integration have been instrumental in addressing our clients concerns related to packaging processes and serialization requirements," says Xyntek's Sr. Vice President, Elliot Abreu.

"I am thrilled to be joining Xyntek's exceptional team," says Thompson. "Xyntek is a globally recognized leader in its sector, and its upbeat culture is one that is absolutely focused, and committed to, being the best."

Hashemian adds, "Because of our accelerated growth in the past few years, this key addition to our top sales management team will help us continue to build the sales platform to enhance our ability to scale and standardize in support of our growth and quality initiatives with Antares Vision of Italy and beyond."

In his new role, Thompson will be responsible for supporting Xyntek's mission to foster partnerships with world-class Pharmaceutical, Health care, and Medical device organizations to provide Information Technology and Real Time Systems Automation Solutions, customized to meet business, technological, and regulatory requirements.

About Xyntek

Headquartered in Yardley, Pennsylvania, Xyntek Inc. is a leading provider of technology consulting and turn-key integrated Information Systems and Automation solutions to the world's leading Life Sciences companies. Xyntek leverages extensive experience in pharmaceutical manufacturing, packaging, and supply chain operations to offer a suite of professional automation systems engineering design & consulting, and integrated packaging automation and information technology solutions & services for serialization, track & trace, & e-Pedigree compliance.

For more information on products and services offered at Xyntek Inc., please call (215) 493-7091 or visit www.xyntekinc.com.

Elliot Abreu
Senior Vice President
Xyntek Inc.
(215) 493-7091 ext. 227

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Xyntek Inc.

Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.